Emcure

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

The stock was listed on July 10, 2024, and made a stellar debut on Indian bourses with the shares getting listed at Rs 1,325.05 on the BSE, a 31.45 per cent premium over its issue price

Shares of Emcure Pharma jumped 6 per cent at Rs 1523.80 a piece on the BSE after the company reported a strong second quarter earnings for the financial year 2024-25 (Q2FY25)

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure

Emcure Pharmaceuticals listing today: According to analysts, Emcure Pharma is quoting at a reasonable valuation with a niche opportunity to invest in the gynaecology & HIV antivirals therapeutic areas

Emcure Pharmaceuticals listing: Stock made a strong market debut as they got listed at Rs 1,325, a 31 per cent premium over the issue price of Rs 1,008 on the NSE and BSE today

Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday

The demand for both issuances reflects the positive sentiment among investors and could be a harbinger for more initial public offerings (IPOs) in the coming weeks, said industry players

The issue, with a price band of Rs 960 to Rs 1,008 per share, will be open for public subscription till July 5. The IPO comprises fresh issuance of equity shares worth Rs 800 crore

Emcure Pharmaceuticals initial public offering is set to open for subscription on Wednesday, July, 3, 2024

Emcure Pharmaceuticals' shares are commanding a premium of over 25 per cent above their price band

Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes

IPO comprises fresh issue of equity shares worth Rs 800 crore and OFS of 13.6 million equity shares by promoters

Litigation before courts in the US and arbitral tribunal in London settled, two sides say

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business

The company had first submitted draft papers for its IPO in August 2021

Emcure, backed by private equity firm Bain Capital, has hired investment banks JP Morgan, Jefferies and Kotak for the IPO, and is targeting a valuation of about $3 billion

The US firm HDT Bio Corp has alleged that Emcure 'willfully and maliciously' violated the Defend Trade Secrets Act and Washington's laws against trade secret theft

Emcure Pharmaceuticals Ltd announced that it has received Emergency Use Authorisation approval for launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild Covid-19.